New Delhi, Aug 16 (PTI) Aurobindo Pharma Ltd on Tuesday said its wholly-owned arm Eugia Pharma Specialties Ltd has received final approval from the US health regulator for its generic version of Vasopressin injection.

The injection is indicated to increase blood pressure in adults who suffer from sudden relaxation of blood vessels.

Also Read | Samsung Galaxy Z Flip 4 & Galaxy Z Fold 4 Pre-Booking in India To Begin Today, Check Details Here.

The approval granted by the US Food and Drug Administration (USFDA) is for manufacturing and marketing of vasopressin injection of strength 20 units/ml multiple-dose vials, Aurobindo Pharma said in a regulatory filing.

The approved product is bioequivalent and therapeutically equivalent to the reference listed drug Vasostrict injection 20 units/ml of Par Sterile Products, LLC (Par), it added.

Also Read | Snapchat+ Hits 1 Million Subscribers, Rolls Out New Features.

Vasopressin Injection is indicated to increase blood pressure in adults with vasodilatory shocks, such as due to post-cardiotomy or sepsis, and remain hypotensive despite fluids and catecholamines.

The product is being launched immediately, the company said.

The approved product has an estimated market size of around USD 606 million for the 12 months ending June 2022, the company said, citing IQVIA data.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)